Skip to main content
. Author manuscript; available in PMC: 2014 Feb 4.
Published in final edited form as: Mol Pharm. 2013 Jan 14;10(2):709–716. doi: 10.1021/mp300507r

Figure 1.

Figure 1

Production, purification, and characterization of TRC105-F(ab')2. (A) Purification of TRC105-F(ab')2 using a Sephadex G-75 column. Arrowhead indicates the fraction used for further in vitro/in vivo studies. (B) SDS-PAGE to confirm the purity of TRC105-F(ab')2 after Sephadex G-75 column purification. Lane 1: molecular weight markers; lane 2: TRC105; lane 3: reaction mixture after pepsin digestion; lane 4: Purified TRC105-F(ab')2. (C) HPLC analysis further confirmed the purity of TRC105-F(ab')2. (D) Mass spectrometry of TRC105-F(ab')2 (~97 kDa) and its parent antibody TRC105 (~148 kDa). Doubly charged ions are also observed (48,473 Da and 73,990 Da) in the mass spectra.